

# ASX release

13 December 2024

## Change of Director's Interest – David Koczkar

In accordance with the Listing Rules, Medibank attaches an Appendix 3Y – Change of Director's Interest Notice for David Koczkar for release to the market.

This document has been authorised for release by Mei Ramsay, Company Secretary.

### For further information please contact:

#### For media

Emily Ritchie  
Hub Lead, External Affairs  
M: +61 429 642 418  
Email: [Emily.Ritchie@medibank.com.au](mailto:Emily.Ritchie@medibank.com.au)

#### For investors/analysts

Colette Campbell  
Hub Lead, Investor Relations  
M: +61 475 975 770  
Email: [investor.relations@medibank.com.au](mailto:investor.relations@medibank.com.au)

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity:</b> MEDIBANK PRIVATE LIMITED
<b>ABN:</b> 47 080 890 259

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	David Koczkar
<b>Date of last notice</b>	27 November 2024

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct (Performance Rights pursuant to the Medibank Private Limited Performance Rights Plan (' <i>Performance Rights Plan</i> '))
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	
<b>Date of change</b>	9 December 2024
<b>No. of securities held prior to change</b>	1,381,928 Performance Rights, being: <ul style="list-style-type: none"><li>728,840 Performance Rights granted under the FY23 Long Term Incentive (<i>LTI</i>); and</li><li>653,088 Performance Rights granted under the FY24 LTI.</li></ul>
<b>Class</b>	Performance Rights
<b>Number acquired</b>	932,801 Performance Rights, being: <ul style="list-style-type: none"><li>174,671 Performance Rights granted under the FY24 Deferred Short Term Incentive (<i>Deferred STI</i>); and</li><li>758,130 Performance Rights granted under the FY25 LTI.</li></ul>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Performance Rights are granted at nil consideration under the terms of the Performance Rights Plan.
<b>No. of securities held after change</b>	2,314,729 Performance Rights, being: <ul style="list-style-type: none"> <li>• 728,840 Performance Rights granted under the FY23 LTI;</li> <li>• 653,088 Performance Rights granted under the FY24 LTI;</li> <li>• 174,671 Performance Rights granted under the FY24 Deferred STI; and</li> <li>• 758,130 Performance Rights granted under the FY25 LTI.</li> </ul>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Grant of Performance Rights under the Performance Rights Plan, being the: <ul style="list-style-type: none"> <li>• FY24 Deferred STI; and</li> <li>• FY25 LTI.</li> </ul>

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Indirect interest in Ordinary Shares in Medibank Private Limited ( <i>Ordinary Shares</i> ) held via Olive Man Investments Pty Ltd
<b>Date of change</b>	N/A
<b>No. of securities held prior to change</b>	1,884,671 Ordinary Shares (indirect).
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	Nil
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	N/A
<b>No. of securities held after change</b>	1,884,671 Ordinary Shares (indirect)
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	N/A

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

---

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.